Sigma-Aldrich acquires Pharmorphix

By Elaine Rigoli

Tampa, Fla., Aug. 9 - Sigma-Aldrich Corp. said Wednesday that it has acquired Pharmorphix Ltd., which will broaden SAFC Pharma's (Sigma's custom manufacturing group) manufacturing services customer base and enhance technology services.

The purchase price, which was not disclosed, was paid in cash.

The mid-year addition of Pharmorphix, which had sales of roughly $5 million over the past 12 months, will not have a material impact on Sigma-Aldrich's sales.

The acquisition is expected to help Sigma-Aldrich achieve its growth goals over the next several years and is expected to be neutral to mildly accretive to earnings in 2006, with no initial charges, according to a news release.

All current employees in good standing, including the existing Pharmorphix management team, will remain with the company.

Pharmorphix is a privately held pharmaceutical company based in Cambridge, England.

Sigma-Aldrich is a life science and technology company with U.S. offices in St. Louis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.